MSD Animal Health, a division of Merck & Co., Inc., completed the acquisition of the aqua business of Elanco Animal Health Incorporated. The completion of this acquisition bolsters MSD Animal Health’s position in the aqua industry with a comprehensive approach to promoting fish health, welfare and sustainability in aquaculture, conservation, and fisheries.
“With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition,” said Rick DeLuca, president, MSD Animal Health. “We are excited to welcome our new colleagues to MSD Animal Health and look forward to working together, driven by our common purpose of the Science of Healthier Animals®.”
As a result of the acquisition, MSD Animal Health now owns innovative products such as CLYNAV®, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease and IMVIXA®, an anti-parasitic sea lice treatment and water treatment products for warm water production, complementing MSD Animal Health’s vaccine portfolio.
The increasing use of medicines and vaccines, nutritionals and supplements for aquatic species is driven by the growing demand for protein and food safety, ensuring a supply of quality food and protecting public health.
